Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Clinical Oncology

• Publication date

  2003-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2003.02.086PMID 14615449
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy

  2003cited by this paper
• Measuring the side effects of taxane therapy in oncology

  2003cited by this paper
• Recent advances in drug-induced neuropathies

  2002cited by this paper
• Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

  2000cited by this paper
• Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

  1998cited by this paper
• Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin

  1997cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.

  1996cited by this paper
• Paclitaxel (taxol)

  1995cited by this paper
• European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

  1994cited by this paper
• Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

  1993cited by this paper
• Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.

  1992cited by this paper
• Quantitative ultrastructural effects of cisplatin (Platinol), carboplatin (JM8), and iproplatin (JM9) on neurons of freshwater snail Lymnaea stagnalis.

  1992cited by this paper
• Cisplatin neuropathy: clinical course and neurophysiological findings

  1992cited by this paper
• Sequences of taxol and cisplatin: a phase I and pharmacologic study.

  1991cited by this paper
• Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

  1991cited by this paper
• Cisplatin neuropathy. Risk factors, prognosis, and protection by WR‐2721

  1988cited by this paper
• Phase I trial of taxol in patients with advanced cancer.

  1987cited by this paper
• WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

  1987cited by this paper
• Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.

  1987cited by this paper
• A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study

  1986cited by this paper
• Phase I/II trials of WR-2721 and cis-platinum.

  1986cited by this paper
• Phase I trials of WR-2721 and cis-platinum.

  1984cited by this paper
• Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.

  1984cited by this paper
• Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties.

  1980cited by this paper
• Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report.

  1979cited by this paper

• Chemotherapy-Induced Peripheral Neuropathy: A Recent Update on Pathophysiology and Treatment

  2024cites this paper
• Advances of Amifostine in Radiation Protection: Administration and Delivery.

  2023cites this paper
• Emerging Approaches for the Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Therapeutic Potential of the C5a/C5aR Axis

  2022cites this paper
• Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial

  2020cites this paper
• Proactive Rehabilitation for Chemotherapy-Induced Peripheral Neuropathy.

  2020cites this paper
• 6-Methoxyflavanone abate cisplatin-induced neuropathic pain apropos anti-inflammatory mechanisms: A behavioral and molecular simulation study.

  2020cites this paper
• Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies.

  2020cites this paper
• Peripheral Neuropathy in Ovarian Cancer

  2020cites this paper
• Peripheral Neuropathy in Ovarian Cancer

  2019cites this paper
• Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents.

  2019cites this paper
• Peripheral Neuropathy in Ovarian Cancer

  2019cites this paper
• Peripheral Neuropathy in Ovarian Cancer

  2018cites this paper
• Peripheral Neuropathy in Ovarian Cancer

  2017cites this paper
• Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy

  2017cites this paper
• New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy

  2016cites this paper
• Effect of lower limb closed kinematic chain exercises on balance in patients with chemotherapy-induced peripheral neuropathy: a pilot study

  2016cites this paper
• The Role of Exercise in Chemotherapy-Induced Peripheral Neuropathy

  2016cites this paper
• A Systematic Review on Neuropathy

  2016cites this paper
• New Practical Approaches to Chemotherapy-Induced Neuropathic Pain: Prevention, Assessment, and Treatment.

  2016cites this paper
• Chronic pain syndromes, mechanisms, and current treatments.

  2015cites this paper
• Taxane induced neuropathy in patients affected by breast cancer: Literature review.

  2015cites this paper
• Oncology Section Task Force on Breast Cancer Outcomes: Clinical Measures of Chemotherapy‐induced Peripheral Neuropathy—A Systematic Review

  2015cites this paper
• Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires.

  2014cites this paper
• Stressing Mitosis to Death

  2014cites this paper
• Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature

  2014cites this paper
• Two drugs are better than one. A short history of combined therapy of ovarian cancer

  2014cites this paper
• Interventions for preventing neuropathy caused by cisplatin and related compounds.

  2014cites this paper
• Nursing research in the Gynecologic Oncology Group.

  2014cites this paper
• Biobehavioral approaches to pain

  2014cites this paper
• Conducting Nursing Intervention Research in a Cooperative Group Setting – A Gynecologic Oncology Group (GOG) Experience

  2014cites this paper
• Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)

  2013cites this paper
• Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.

  2013cites this paper
• Chemotherapy-Induced Peripheral Neuropathy in Pediatric Cancer Patients.

  2013influential citation
• Can Medical Herbs Stimulate Regeneration or Neuroprotection and Treat Neuropathic Pain in Chemotherapy-Induced Peripheral Neuropathy?

  2013influential citation
• Chemotherapy‐induced peripheral neurotoxicity: A critical analysis

  2013cites this paper
• Neuropatia induïda per Bortezomib. Caracterització i factors de risc en un model experimental

  2012cites this paper
• Therapy of human papillomavirus-related disease.

  2012cites this paper
• Obwodowa neuropatia wywołana chemioterapią. Część II. Zapobieganie

  2012cites this paper
• Neuropathy Secondary to Chemotherapy: A Real Issue for Cancer Survivors

  2012influential citation
• Current Knowledge on Pancreatic Cancer

  2012cites this paper
• Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.

  2012cites this paper
• Peripheral Neuropathy in Ovarian Cancer

  2012cites this paper
• Peripheral Neuropathy in Ovarian Cancer

  2012cites this paper
• Chemotherapy-induced peripheral neuropathy. Part II. Prevention

  2012cites this paper
• The role of the organic cation/carnitine transporters in the uptake and neurotoxicity of oxaliplatin

  2012cites this paper
• Treatment strategies for chemotherapy-induced peripheral neuropathy: potential role of exercise

  2011cites this paper
• Chemotherapy‐Induced Peripheral Neuropathy: Prevention and Treatment

  2011cites this paper
• The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial

  2011cites this paper
• A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA

  2011cites this paper
• Neuropatía inducida por quimioterapia: un problema no resuelto

  2010cites this paper
• Neuromuscular Disease and Spinal Cord Compression

  2010cites this paper
• Measures of chemotherapy‐induced peripheral neuropathy: a systematic review of psychometric properties

  2010cites this paper
• Patient‐reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer

  2010cites this paper
• [Chemotherapy-induced peripheral neuropathy: an unresolved issue].

  2010cites this paper
• Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184.

  2010cites this paper
• Chemotherapy-induced peripheral neurotoxicity

  2010cites this paper
• Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents.

  2010cites this paper
• Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies

  2010cites this paper
• Patient-Reported Outcomes in Chemotherapy-Induced Peripheral Neuropathy: A Review

  2010cites this paper
• Therapy of chemotherapy‐induced peripheral neuropathy

  2009cites this paper
• Chemotherapy Induced Peripheral Neuropathies (CIPNs): A Biobehavioral Approach

  2009influential citation
• A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.

  2009cites this paper
• Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.

  2008cites this paper
• Peripheral nerve damage associated with administration of taxanes in patients with cancer.

  2008cites this paper
• Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone.

  2008cites this paper
• TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study

  2008cites this paper
• Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.

  2008cites this paper
• Chemotherapy‐induced neuropathy

  2008cites this paper
• Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice.

  2007cites this paper
• Cytoprotective agents used in the treatment of patients with cancer.

  2007cites this paper
• Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions.

  2007cites this paper
• Novel Microtubule-Stabilizing Agents : Preclinical and Clinical Studies

  2007cites this paper
• Neuroprotection During Chemotherapy: A Systematic Review

  2007cites this paper
• Peripheral neuropathy related to chemotherapy.

  2007cites this paper
• Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy.

  2007cites this paper
• Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.

  2007cites this paper
• Vitamin e for the prevention of chemotherapy-induced peripheral neuropathy: rationale for an ongoing clinical trial.

  2007cites this paper
• Radiation-induced peripheral neuropathies: Etiopathogenesis, risk factors, differential diagnostics, symptoms and treatment

  2007cites this paper
• Peripheral neuropathy induced by microtubule-stabilizing agents.

  2006cites this paper
• The role of growth factors in the prevention and treatment of chemotherapy-induced peripheral neurotoxicity.

  2006cites this paper
• Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity

  2006cites this paper
• Chemotherapy-induced peripheral neuropathy: Underreported and underappreciated

  2006cites this paper
• Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.

  2006cites this paper
• Peripheral Neuropathy Due to Chemotherapy and Radiation Therapy

  2006cites this paper
• Drug Treatment for Sequelae After Gynecologic Cancer Treatment

  2006cites this paper
• Neurologic toxicities of cancer therapies

  2006cites this paper
• Scale for Chemotherapy-induced Long-term Neurotoxicity (SCIN): Psychometrics, Validation, and Findings in a Large Sample of Testicular Cancer Survivors

  2006cites this paper
• A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.

  2005cites this paper
• Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group

  2005cites this paper
• Commentary: The Pharmacological Antioxidant Amifostine—Implications of Recent Research for Integrative Cancer Care

  2005cites this paper
• Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy.

  2005cites this paper
• Chemotherapy-induced peripheral neurotoxicity

  2004cites this paper